MedTrace Logo

The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease

NCT05777616 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 166

Last updated 2023-03-21

No results posted yet for this study

Summary

The IFX adherence to CD in China was not high. Medicine concerns may be predictive factor of adherence. By enhancing knowledge and relieving medicine concerns, we may increase patients' adherence to IFX.

Conditions

  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Yan Chen · 2nd Affiliated Hospital, School of Medicine, Zhejiang University,China

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2021-12-28
Completion
2021-12-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05777616 on ClinicalTrials.gov